The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory ...

With the recommended phase 2 regimen, a response occurred in 80% of the patients (including in 61% of those with extramedullary ... relapsed or refractory multiple myeloma. We conducted an ongoing ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

Two months after the bone scan, CT-guided biopsy of the thoracic ... patients with chemorefractory multiple myeloma, even at the stage of terminal illness with extramedullary plasmacytoma.